New Hair Loss Treatments: What Is Actually in Late-Stage Trials

Written Sep 14, 2026Sources re-read Sep 24, 2026

General information — nobody clinical checked this

Nobody who works on this site holds a medical qualification, and it has never been past a clinician of any kind. Every grade on it is arithmetic on public documents, not a clinical opinion about anyone. Talk to a doctor or a dermatologist before starting, stopping or combining any treatment.

Diagnosis has to come first. Thyroid disease, low iron, alopecia areata, scarring alopecias, a medicine you are already taking and a heavy shed after illness or weight loss all thin hair, and none of them is pattern baldness — so none of them is fixed by a product bought for it. If you are not sure which you have, that is the first thing to ask, and what a dermatologist checks sets out what that appointment looks like.

Nothing on this page is a dose, a regimen or an instruction. How much of anything, how often and whether at all are decisions for a prescriber and the product’s own label.

Nothing new has been approved for male pattern hair loss. That is the short answer to the question, and it has been the answer for a long time: the two approved treatments both date from an earlier era of drug development, and every candidate since has either failed or is still in trials.

What has changed is that two candidates now have published late-stage results, and both of their makers have said what they intend to do next. Those are company announcements, and this page treats them as exactly that.

A topical androgen-receptor drug with phase III results

Cosmo Pharmaceuticals announced twelve-month phase III results for a topical clascoterone solution on 15 April 2026. By the company's account the programme — two trials it calls SCALP 1 and SCALP 2 — enrolled 1,465 subjects across 51 study centres in the United States and Europe, and measured target-area hair count. Men who stayed on the drug for the full year showed what the release describes as a statistically significant 2.39-fold improvement in that count against men switched to the vehicle after six months.

The company also said its US filing is planned for early 2027, with a European submission alongside it.

Read that carefully, because the gap between the sentences matters. A filing planned is not a filing made; a filing made is not an approval; and results announced by the company running the trial are not the same as results published in a journal and picked apart by people with nothing at stake. Every one of those steps has killed hair-loss candidates before. If it clears them, it would be a genuinely different mechanism from anything approved — which is why it is worth watching rather than worth waiting for.

A follicle-regeneration candidate at an earlier stage

Pelage Pharmaceuticals announced phase 2a results for a topical it calls PP405 on 17 June 2025. The trial enrolled 78 men and women, applied the drug or a placebo to the scalp over four weeks and followed participants to twelve weeks. The company's stated primary endpoint was safety and tolerability, and it reported the drug was well tolerated with no systemic absorption detected in blood.

On efficacy, the release says that among men with a higher degree of hair loss, 31% of those treated showed a greater than 20% increase in hair density at week eight, against 0% of those on placebo. The company said it planned to start phase 3 studies in 2026.

Seventy-eight people is a small trial and a phase 2a is an early one. A subgroup result inside a small early trial whose primary endpoint was safety is a reason to run a bigger trial, not a reason to believe a number. That is not scepticism about this particular drug; it is what a phase 2a is for.

What the new approvals actually were

If you have seen headlines about newly approved hair-loss drugs in the last few years, they were almost certainly about a different condition. The FDA approved baricitinib for severe alopecia areata in adults on 13 June 2022, ritlecitinib for severe alopecia areata in adults and adolescents from twelve years old on 23 June 2023, and deuruxolitinib for adults with severe alopecia areata on 25 July 2024.

Alopecia areata is autoimmune: the immune system attacks hair follicles, typically producing round, smooth patches. It is not pattern baldness, these drugs are not approved for pattern baldness, and they carry the kind of warnings that come with medicines suppressing part of the immune system. What those approvals cover, and what they cost in risk is a separate page, because it is a separate disease.

What "new" usually means on a product page

Most products advertised as new hair-loss treatments are not new treatments. They are new arrangements of things that already exist, and there are three recurring shapes.

A new delivery of an old active. A foam instead of a liquid, a spray instead of a dropper, a serum instead of a shampoo. The active ingredient is the same molecule with the same evidence behind it; what has changed is how pleasant it is to use, which is a real benefit and a different claim.

A new combination. Two or three actives mixed into one compounded bottle. Combinations are studied, and some have trials behind them, but a combination is not automatically stronger than its parts and a compounded mixture has no approved label describing what it does. The FDA's April 2025 alert about compounded topical finasteride was, in part, about exactly this market.

A new brand. A subscription wrapper around a generic, with photography. Nothing about the molecule has changed at all.

None of those is dishonest in itself. They become dishonest when the word new is doing the work that evidence should be doing, and the test is simple: ask which active ingredient it contains, and then ask what has been published about that ingredient rather than about the bottle.

How to read the next announcement

Which condition? Alopecia areata, pattern hair loss and telogen effluvium are different problems, and a drug approved for one says nothing about the others.
Which phase? Phase 2a asks whether a drug is tolerable and worth pursuing. Phase 3 asks whether it works well enough to approve.
Who is reporting? A company release about its own trial is a legitimate source for what the company claims, and nothing more.
Endpoint or subgroup? A result in a slice of a trial is a hypothesis; the pre-specified endpoint is the test.
Filed, or approved? A planned filing date is a plan.

Until a regulator decides, nothing in the pipeline has a tier. The index of hair-loss treatments only holds products that can answer both of its questions today, and "approval expected" is not an answer to either. In the meantime, the honest version of "new" is usually a new delivery of an old active, which is what topical treatments beyond minoxidil is about.

New treatments, honestly

Is there a new hair loss treatment in 2026?

Not an approved one for pattern hair loss. Two candidates have published late-stage results: a topical clascoterone solution whose maker announced twelve-month phase III results in April 2026 and a US filing planned for early 2027, and an earlier-stage topical whose maker reported phase 2a results in June 2025 and said phase 3 would start in 2026. Both are company announcements about their own trials, and neither is a regulatory decision.

What about the hair loss drugs the FDA approved recently?

Those approvals were for alopecia areata, an autoimmune condition, not for male pattern baldness. Baricitinib was approved for severe alopecia areata in June 2022, ritlecitinib in June 2023 and deuruxolitinib in July 2024. They work by suppressing part of the immune response, which is why they are prescription medicines with serious warnings and why they are not offered for pattern hair loss.

Should I wait for something better instead of starting treatment?

That is a question for a doctor who knows your history, and it is worth asking, because pattern hair loss is progressive and the approved treatments act on follicles that are still producing hair. What can be said here is that an announced filing date is not an approval date and that hair-loss candidates have failed at exactly this stage before.

Can I join a trial?

Trials for hair-loss candidates do recruit, and public registries list them with their locations and their eligibility criteria. Whether a trial is appropriate for you is a conversation with a doctor, and a trial is research rather than treatment — the point is to find out whether something works, which means it may not.

Everything here is graded on the same two questions in the index of hair-loss treatments, and the condition itself is set out in male pattern baldness. Information only, and nobody medically qualified has read it.